154 related articles for article (PubMed ID: 35816278)
1. Paxlovid-Tacrolimus Drug-Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19.
Berar Yanay N; Bogner I; Saker K; Tannous E
Clin Drug Investig; 2022 Aug; 42(8):693-695. PubMed ID: 35816278
[No Abstract] [Full Text] [Related]
2. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
Prikis M; Cameron A
Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
[TBL] [Abstract][Full Text] [Related]
3. Correspondence on 'Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series'.
Zhou XX; Ji HJ
Eur J Hosp Pharm; 2024 Feb; 31(2):178-179. PubMed ID: 36737228
[No Abstract] [Full Text] [Related]
4. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.
Guzmán Cordero C; Saez-Torres de Vicente M
Eur J Hosp Pharm; 2024 Feb; 31(2):175-177. PubMed ID: 36535689
[TBL] [Abstract][Full Text] [Related]
5. Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection.
Fishbane S; Hirsch JS; Nair V
Am J Kidney Dis; 2022 Apr; 79(4):480-482. PubMed ID: 35032591
[No Abstract] [Full Text] [Related]
6. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
Transpl Int; 2024; 37():12360. PubMed ID: 38596505
[TBL] [Abstract][Full Text] [Related]
7. The effects of nirmatrelvir/ritonavir on tacrolimus levels in lung transplant recipients: A single-center study.
Wang X; Du W; Zhang D; Chen W; Zuo X
Pulm Pharmacol Ther; 2024 Mar; 84():102280. PubMed ID: 38065402
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 update: Prescription of Paxlovid by pharmacists.
Med Lett Drugs Ther; 2022 Aug; 64(1656):e124. PubMed ID: 35921075
[No Abstract] [Full Text] [Related]
9. Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions.
Shen D; Gong Y; Qian Y; Zhu J; Gao J
J Int Med Res; 2024 May; 52(5):3000605241247705. PubMed ID: 38698526
[TBL] [Abstract][Full Text] [Related]
10. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.
Young C; Papiro T; Greenberg JH
Pediatr Nephrol; 2023 Apr; 38(4):1387-1388. PubMed ID: 35982345
[TBL] [Abstract][Full Text] [Related]
11. Paxlovid for treatment of COVID-19.
Med Lett Drugs Ther; 2022 Jan; 64(1642):9-10. PubMed ID: 35134040
[No Abstract] [Full Text] [Related]
12. A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient.
Lo CM; Chen WH; Tsai MY; Lu HI; Hsiao YH; Chuang KH; Chen Y; Wu HF; Huang KT; Wang YH
J Cardiothorac Surg; 2024 Mar; 19(1):132. PubMed ID: 38491538
[TBL] [Abstract][Full Text] [Related]
13. Covid-19: NICE plans to expand Paxlovid eligibility to 1.4 million more people.
Mahase E
BMJ; 2024 Jan; 384():q59. PubMed ID: 38212056
[No Abstract] [Full Text] [Related]
14. Covid-19: What is the evidence for the antiviral Paxlovid?
Extance A
BMJ; 2022 Apr; 377():o1037. PubMed ID: 35477536
[No Abstract] [Full Text] [Related]
15. The future of Paxlovid for COVID-19.
Burki T
Lancet Respir Med; 2022 Jul; 10(7):e68. PubMed ID: 35623373
[No Abstract] [Full Text] [Related]
16. Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid.
Wang Y; Chen X; Xiao W; Zhao D; Feng L
J Infect; 2022 Nov; 85(5):e134-e136. PubMed ID: 35995309
[No Abstract] [Full Text] [Related]
17. Three more points about Paxlovid for covid-19.
Phizackerley D
BMJ; 2022 Jun; 377():o1397. PubMed ID: 35672048
[No Abstract] [Full Text] [Related]
18. Covid-19: FDA authorises pharmacists to prescribe Paxlovid.
Tanne JH
BMJ; 2022 Jul; 378():o1695. PubMed ID: 35803606
[No Abstract] [Full Text] [Related]
19. Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study.
Buchynskyi M; Oksenych V; Kamyshna I; Kamyshnyi O
Viruses; 2024 Jan; 16(1):. PubMed ID: 38257811
[TBL] [Abstract][Full Text] [Related]
20. Association Between Paxlovid and Mortality Rates in Critically Ill Patients With COVID-19 Receiving Invasive Mechanical Ventilation: A Retrospective Cohort Study.
Yang MJ; Jiang L; Xu L; Guo SL
Chest; 2024 Jan; 165(1):128-131. PubMed ID: 37473858
[No Abstract] [Full Text] [Related]
[Next] [New Search]
